FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
Executive Summary
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.
You may also be interested in...
Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal
Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19
Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal
Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19
King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004